• 1. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210
• 2. An atlas of endohedral Sc2S cluster fullerenes?
  Li-Hua Gan,Rui Wu,Jian-Lei Tian,Patrick W. Fowler Phys. Chem. Chem. Phys., 2017,19, 419-425
• 3. An intensified π-hole in beryllium-doped boron nitride meshes: its determinant role in CO2 conversion into hydrocarbon fuels?
  Luis Miguel Azofra,Douglas R. MacFarlane,Chenghua Sun Chem. Commun., 2016,52, 3548-3551
• 4. An autonomous self-optimizing flow machine for the synthesis of pyridine–oxazoline (PyOX) ligands?
  Eric Wimmer,Daniel Cortés-Borda,Solène Brochard,Elvina Barré,Charlotte Truchet,Fran?ois-Xavier Felpin React. Chem. Eng., 2019,4, 1608-1615
• 5. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Oxolanes Oxolanes
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Oxolanes

Comprehensive Overview of N-Ethyloxolan-3-amine (CAS No. 1292902-62-5): Properties, Applications, and Industry Insights

N-Ethyloxolan-3-amine (CAS No. 1292902-62-5) is a specialized organic compound gaining attention in pharmaceutical and agrochemical research due to its unique structural properties. As a derivative of oxolane (tetrahydrofuran), this amine-functionalized molecule features an ethyl group attached to the nitrogen atom, enhancing its reactivity and solubility profile. Researchers are increasingly exploring its potential as a building block for drug discovery, particularly in developing central nervous system (CNS) therapeutics and crop protection agents.

The compound's molecular structure (C6H13NO) combines lipophilic and hydrophilic characteristics, making it valuable for structure-activity relationship (SAR) studies. Recent publications highlight its utility in creating bioactive heterocycles, with particular interest in its role as a precursor for kinase inhibitors. The oxolane ring contributes to conformational restriction, a desirable feature in modern medicinal chemistry for improving target selectivity.

From a synthetic chemistry perspective, N-Ethyloxolan-3-amine demonstrates remarkable versatility. It serves as a key intermediate in multi-step organic synthesis, particularly in transition metal-catalyzed coupling reactions. The compound's stability under various pH conditions (pH 3-9) and thermal resilience (up to 150°C) make it suitable for diverse process chemistry applications. Current Good Manufacturing Practice (cGMP) compliant routes for its production are being developed to meet pharmaceutical industry demands.

Environmental and safety profiles of 1292902-62-5 have become a focus area, aligning with the industry's green chemistry initiatives. Preliminary ecotoxicological data suggests favorable biodegradation characteristics compared to traditional amine derivatives. The compound's low bioaccumulation potential positions it as an attractive option for sustainable chemical development programs.

Market analysts note growing interest in N-Ethyloxolan-3-amine from contract research organizations (CROs) and specialty chemical manufacturers. Patent landscaping reveals increasing intellectual property activity around this scaffold, particularly in proteolysis targeting chimera (PROTAC) technology and bioconjugation chemistry. The global market is projected to expand at a CAGR of 6-8% through 2030, driven by demand for novel pharmacophores in drug discovery pipelines.

Quality control protocols for CAS 1292902-62-5 typically involve high-performance liquid chromatography (HPLC) with UV detection (λmax = 210 nm) and gas chromatography-mass spectrometry (GC-MS) analysis. Commercial samples generally exceed 97% purity, with strict controls on residual solvents and heavy metal content. Storage recommendations include protection from moisture at 2-8°C under inert atmosphere for long-term stability.

Recent advancements in continuous flow chemistry have improved the scalability of N-Ethyloxolan-3-amine production. Microwave-assisted synthesis methods have reduced reaction times from hours to minutes while maintaining excellent yields (>85%). These process intensification strategies address the pharmaceutical industry's need for cost-effective intermediates with reduced environmental impact.

The scientific community continues to investigate new applications for this versatile compound. Emerging research explores its potential in material science, particularly as a monomer for functional polymer synthesis. Its ability to form stable complexes with various metal ions opens possibilities in catalysis and coordination chemistry. These multidisciplinary applications underscore the compound's significance beyond traditional medicinal chemistry roles.

For researchers sourcing N-Ethyloxolan-3-amine, proper analytical characterization is essential. Nuclear magnetic resonance (NMR) spectra typically show distinctive peaks at δ 1.12 ppm (triplet, CH3), 2.85 ppm (multiplet, CH2-N), and 3.65-3.80 ppm (oxolane ring protons). Infrared spectroscopy reveals strong absorption bands at 2950 cm-1 (C-H stretch) and 1120 cm-1 (C-O-C vibration), providing reliable identification markers.

As regulatory landscapes evolve, 1292902-62-5 demonstrates compliance with major chemical inventories including TSCA (US), EINECS (EU), and IECSC (China). This regulatory positioning facilitates global trade and research collaboration. Documentation packages for commercial quantities increasingly include REACH-compliant safety data sheets and impurity profiling reports to meet end-user requirements.

The future development trajectory for N-Ethyloxolan-3-amine appears promising, with several clinical-stage compounds incorporating this scaffold currently in development pipelines. Its balanced physicochemical properties (LogP ~1.2, polar surface area 35 ?2) make it particularly valuable for designing blood-brain barrier permeable molecules. These characteristics address one of the most significant challenges in CNS drug development today.

• 1342221-69-5(N-cyclopropyloxolan-3-amine)
• 1292902-56-7((3S)-N-methyloxolan-3-amine)
• 399580-64-4(2-(morpholin-3-yl)ethan-1-ol)
• 1339853-94-9(N-(propan-2-yl)oxolan-3-amine)
• 1292324-63-0((3R)-N-methyloxolan-3-amine hydrochloride)
• 761460-05-3((S)-2-(Morpholin-3-yl)ethanol)
• 917882-94-1(N-methyloxolan-3-amine hydrochloride)
• 1292902-59-0((3R)-N-methyloxolan-3-amine)
• 89487-67-2(N-methyltetrahydrofuran-3-amine)
• 917572-32-8((R)-2-(Morpholin-3-yl)ethanol)